dc.contributor | JMI Labs | |
dc.contributor | Universidade Federal de São Paulo (UNIFESP) | |
dc.contributor | Tufts Univ | |
dc.creator | Sader, H. S. | |
dc.creator | Biedenbach, D. J. | |
dc.creator | Jones, R. N. | |
dc.date.accessioned | 2016-01-24T12:34:02Z | |
dc.date.accessioned | 2022-10-07T21:29:38Z | |
dc.date.available | 2016-01-24T12:34:02Z | |
dc.date.available | 2022-10-07T21:29:38Z | |
dc.date.created | 2016-01-24T12:34:02Z | |
dc.date.issued | 2003-09-01 | |
dc.identifier | Diagnostic Microbiology and Infectious Disease. New York: Elsevier B.V., v. 47, n. 1, p. 361-364, 2003. | |
dc.identifier | 0732-8893 | |
dc.identifier | http://repositorio.unifesp.br/handle/11600/27392 | |
dc.identifier | 10.1016/S0732-8893(03)00052-X | |
dc.identifier | WOS:000185384500009 | |
dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/4029555 | |
dc.description.abstract | A total of 48,440 Enterobacteriaceae isolates collected consecutively from patients hospitalized in participant SENTRY Antimicrobial Surveillance Program sites in four international regions (Asia-Pacific, Europe, Latin America, and North America) were tested by reference broth microdilution method against the most commonly used antimicrobial agents. the most active compounds could be divided in 3 groups based on their spectrum of activity. the first group included meropenem and imipenem, with 99.9% susceptibilty (S) rates for the Enterobacteriaceae. the second group includes amikacin (97.3% S) and cefepime (97.2% S); and a third active group had a rank order of susceptibility of: gatifloxacin = levofloxacin (91.7% S) > ceftazidime (91.4% S) > ceftriaxone (91.2% S) > aztreonam (91.1% S) > gentamicin (90.6% S) > piperacillin/tazobactam = ciprofloxacin (90.5% susceptibility). These latter antimicrobial agents presented susceptibility rates of approximately 90% (89.8%-91.7%). Continued resistance surveillance by various programs remain necessary to monitor the in vitro effectiveness of antimicrobial agents currently used in clinical practice. (C) 2003 Elsevier Inc. All rights reserved. | |
dc.language | eng | |
dc.publisher | Elsevier B.V. | |
dc.relation | Diagnostic Microbiology and Infectious Disease | |
dc.rights | http://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy | |
dc.rights | Acesso restrito | |
dc.title | Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48,440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2001) | |
dc.type | Artigo | |